New Two-Drug attack on tough blood cancers begins human testing
Disease control
Recruiting now
This is an early-stage study testing the safety and initial effectiveness of a new drug combination called UB-VV111 plus rapamycin. It is for adults with certain advanced B-cell blood cancers (like lymphoma and leukemia) that have come back or stopped responding to other treatmen…
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC